NASDAQ:IVA

Inventiva S.a. Stock News

etoro logo Buy IVA
*Your capital is at risk
$4.04
-0.0500 (-1.22%)
At Close: Jun 03, 2026
Daix (France), New York (United States), March 23, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on th
Inventiva S.A. (IVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
The mean of analysts' price targets for Inventiva (IVA) points to a 136.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys
Shares of Inventiva S.A. Sponsored ADR (NASDAQ: IVA - Get Free Report) have earned an average recommendation of "Buy" from the ten research firms that are presently covering the company, MarketBeat re
Daix (France), New York City (New York, United States) , February 17, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company foc
Inventiva (NASDAQ: IVA - Get Free Report) and Vera Therapeutics (NASDAQ: VERA - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on t
Daix (France), New York (United States), February 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on
A surge in Inventiva shares, up about 50% in the first few weeks of 2026, highlights investors' appetite for ​betting on the loss-making French biotech, which is on the verge of entering the fast-gr
Does Inventiva S.A. Sponsored ADR (IVA) have what it takes to be a top stock pick for momentum investors?

Inventiva S.A. (IVA) Presents at 44th Annual J.P.

02:16pm, Thursday, 15'th Jan 2026
Inventiva S.A. (IVA) Presents at 44th Annual J.P.
The consensus price target hints at a 200.6% upside potential for Inventiva (IVA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimat
Inventiva S.A. Sponsored ADR (NASDAQ: IVA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven ratings firms that are presently covering the firm, MarketBeat.com rep
Daix (France), New York City, (New York, United States), November 21, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company foc
Daix (France), New York City (New York, United States), November 17, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focu

Wall Street Week Ahead

07:05am, Sunday, 16'th Nov 2025
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE